101
|
Win N, Peterkin MA, Watson WH. The therapeutic value of HPA-1a-negative platelet transfusion in post-transfusion purpura complicated by life-threatening haemorrhage. Vox Sang 1995; 69:138-9. [PMID: 8585196 DOI: 10.1111/j.1423-0410.1995.tb01685.x] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Post-transfusion purpura (PTP) was diagnosed in a female patient 1 week after transfusion for hysterectomy. Despite treatment with oral steroids and intravenous immunoglobulin, platelet counts remained low, and the patient developed profuse rectal bleeding. Random platelet transfusion is reported to be ineffective in PTP. We report a case in which the transfusion of HPA-la negative platelets provided good increment and clinical haemostasis before intravenous immunoglobulin could have had an effect.
Collapse
|
102
|
Imbach P. Immune thrombocytopenia in children: the immune character of destructive thrombocytopenia and the treatment of bleeding. Semin Thromb Hemost 1995; 21:305-12. [PMID: 8588157 DOI: 10.1055/s-2007-1000651] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
It is now recognized that different forms of destructive thrombocytopenia due to antibody binding to platelets exist, which can be differentiated by sensitive new assays. Thus, the name has been changed from idiopathic to immune thrombocytopenic purpura (ITP). The immune character of ITP has been further supported by the success of treatment with human antibody concentrate-immunoglobulin treatment. During different studies of ITP in children, it has been recognized that only patients with bleeding in addition to a platelet count less than 20 x 10(9)/L need to be treated. The various forms of treatment are reviewed.
Collapse
|
103
|
Arbiser JL, Dzieczkowski JS, Harmon JV, Duncan LM. Leukocytoclastic vasculitis following staphylococcal protein A column immunoadsorption therapy. Two cases and a review of the literature. ARCHIVES OF DERMATOLOGY 1995; 131:707-9. [PMID: 7778924] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
BACKGROUND Protein A immunoadsorption is a novel therapy for the treatment of diseases mediated by pathogenic autoantibodies. This procedure consists of circulating patients' plasma through a column containing staphylococcal protein A, which binds to the Fc portion of IgG, enabling removal of IgG. Presently, protein A immunoadsorption is used in the treatment of idiopathic thrombocytopenic purpura, but may be more widely used as an immunomodulator in human immunodeficiency virus infection and metastatic carcinoma. OBSERVATIONS We present two histologically documented cases of leukocytoclastic vasculitis in the setting of protein A immunoadsorption. This potentially severe adverse effect is probably more common than the literature reflects and should be recognized by physicians who are treating patients with protein A column pheresis. CONCLUSIONS The pathogenesis of protein A therapy-associated leukocytoclastic vasculitis remains unclear. Further study of vasculitis in the setting of protein A column pheresis may lead to modifications of this therapy, resulting in fewer adverse effects. Protein A-associated leukocytoclastic vasculitis may serve as a useful model of the relation of immune complexes and vasculitis.
Collapse
|
104
|
Mobini N, Sarela A, Ahmed AR. Intravenous immunoglobulins in the therapy of autoimmune and systemic inflammatory disorders. Ann Allergy Asthma Immunol 1995; 74:119-28; quiz 128-33. [PMID: 7697470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
OBJECTIVE The focus of this review is to summarize the mechanism and the adverse side-effects of Intravenous Immunoglobulin (IVIg) therapy, and to highlight the current cumulative experience of its use in the treatment and management of autoimmune and systemic inflammatory diseases. DATA SOURCES Detailed search of the literature was done. Studies involving only humans were considered for clinical evaluation. Animal studies were used only for understanding mechanisms of action. The NIH Consensus Conference of May 1990 and the Australian Society for Blood Transfusion of July 1993 were used for guidelines. STUDY SELECTION Material was taken only from peer reviewed journals. RESULTS It appears that IVIg may act by more than one mechanism of action. It is unclear whether the mechanism is different in different diseases and whether more than one mechanism may apply to any disease or clinical state. The incidence and gravity of serious side effects appears low. It is the mainstay of treatment of immune thrombocytopenia purpura and Kawasaki disease. CONCLUSION IVIg is a safe and effective therapeutic modality that can be added to the repertoire of various agents used to treat autoimmune and systemic inflammatory diseases. Long-term prospective studies are needed to define indications, dose-schedules, duration of therapy, and influence on the clinical courses of chronic diseases better.
Collapse
|
105
|
Weiner P, Ganem R, Schechter Y. [Post-transfusion purpura]. HAREFUAH 1994; 127:525-7, 575. [PMID: 7813928] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Post-transfusion purpura (PTP) is a rare syndrome that may develop a week after blood transfusion. In this syndrome, which occurs mainly in women, blood transfusion is followed by severe thrombocytopenia a week later. A 72-year-old woman with this syndrome is presented. High-dose intravenous gamma-globulin resulted in prompt resolution of her thrombocytopenia. The basic pathophysiologic mechanism of PTP is the development of an alloantibody to a human platelet antigen. The mystery of PTP is why the patients' own, as well as transfused PLA1-negative platelets, are destroyed.
Collapse
|
106
|
Olsen KM, Marx MA, Monaghan MS, Barnes E, Ackerman BH, Pappas AA. Phenytoin and plasmapheresis: importance of sampling times and impact of obesity. Ther Drug Monit 1994; 16:624-8. [PMID: 7878706] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
The effect of plasmapheresis (PP) on total and free phenytoin clearance is reported. An obese patient with the diagnosis of thrombotic thrombocytopenic purpura (TTP) was treated with PP. Twelve episodes of PP, having exchange volumes of 1.5-2.25 times the plasma volume with a mean +/- SD 7.7 +/- 0.8 L of plasma removed, were studied. A significant (p < 0.05) difference was observed with a mean change in plasma phenytoin concentrations from pre- to end-PP of 7.32 +/- 2.5 mg/L compared to 1.98 +/- 0.7 mg/L observed pre-PP to 1 h post-PP. These values corresponded to 48.4 +/- 11.6 and 15.0 +/- 6.7% decreases in phenytoin concentrations at the two aforementioned time periods. To prevent misinterpretation of plasma phenytoin concentrations, samples should not be obtained for at least 2 h after PP.
Collapse
|
107
|
Buchanan GR. Treatment of childhood idiopathic thrombocytopenic purpura. J Pediatr 1994; 125:503. [PMID: 8071767 DOI: 10.1016/s0022-3476(05)83308-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
|
108
|
Ozsoylu S. Treatment of childhood idiopathic thrombocytopenic purpura. J Pediatr 1994; 125:503-4. [PMID: 8071768 DOI: 10.1016/s0022-3476(05)83309-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
|
109
|
Herrington A, Mahmood A, Berger R. Treatment options in sulfamethoxazole-trimethoprim-induced thrombocytopenic purpura. South Med J 1994; 87:948-50. [PMID: 8091265 DOI: 10.1097/00007611-199409000-00019] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
We describe two female patients who had severe sulfamethoxazole-trimethoprim-induced thrombocytopenic purpura. One case occurred shortly after initiating therapy, whereas the other began on the seventh day of treatment. Both patients presented a platelet count below 5,000/microL, extensive purpura, and significant vaginal bleeding. Treatment with systemic corticosteroids resulted in rapid resolution of the thrombocytopenia in the first patient, but had no immediate effect in the other. High-dose intravenous immunoglobulin was effective in correcting the thrombocytopenia in this second instance. Both patients were discharged with a tapering 4-week course of oral prednisone and have remained well since.
Collapse
|
110
|
De Vlieghere FC, Peetermans WE, Vermylen J. Aseptic granulocytic meningitis following treatment with intravenous immunoglobulin. Clin Infect Dis 1994; 18:1008-10. [PMID: 8086530 DOI: 10.1093/clinids/18.6.1008] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
|
111
|
Katai M, Aizawa T, Ohara N, Hiramatsu K, Hashizume K, Yamada T, Kitano K, Saito H, Shinoda T, Wakata S. Acquired amegakaryocytic thrombocytopenic purpura with humoral inhibitory factor for megakaryocyte colony formation. Intern Med 1994; 33:147-9. [PMID: 8061390 DOI: 10.2169/internalmedicine.33.147] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
A 67-year-old man with thrombocytopenia, and amegakaryocytic but otherwise normal bone marrow, was evaluated. Antibody against thrombocytes was negative and the half-life of thrombocytes was normal. In vitro clonal culture of the patient's bone marrow cells yielded no megakaryocyte colony with normal granulocyte-macrophage and erythroid colony formation. Megakaryocyte colony formation of the control bone marrow cells was significantly suppressed by the addition of the patient's serum to the culture, suggesting the existence of humoral inhibitory factor(s) for megakaryocyte colony formation. Therapeutic trials with plasma exchange, cyclosporine, prednisolone, and cyclosporine plus prednisolone were all unsuccessful, but serious bleeding has been absent.
Collapse
|
112
|
Yamaguchi K, Nomura S, Miyazaki Y, Miyake T, Kido H, Kawakatsu T, Fukuroi T, Suzuki M, Yanabu M, Kokawa T. Activation of transfused platelets in a patient with amegakaryocytic thrombocytopenic purpura. Transfusion 1994; 34:186-7. [PMID: 8310498 DOI: 10.1046/j.1537-2995.1994.34294143957.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
|
113
|
Billett HH. Thrombocytopenia in pregnancy. JOURNAL OF THE ASSOCIATION FOR ACADEMIC MINORITY PHYSICIANS : THE OFFICIAL PUBLICATION OF THE ASSOCIATION FOR ACADEMIC MINORITY PHYSICIANS 1994; 5:117-122. [PMID: 7949823] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
Abstract
The implications of thrombocytopenia in pregnancy vary with the etiology of the thrombocytopenia. This article focuses on defining what those etiologies are and assessing risk and therapy for each. Most important, the need to diagnose the largest and most benign entity of incidental thrombocytopenia is emphasized so that patients can be reassured and not subjected to further intervention. The angiopathic entities of preeclampsia, HELLP syndrome (hemolytic anemia, elevated liver function tests, and low platelets), disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, and hemolytic-uremic syndrome may also cause severe thrombocytopenia. The controversy surrounding the particular therapeutic dilemma of immune thrombocytopenic purpura is explored, with evaluation of the actual danger to the mother, method of delivery, and treatment for the neonate. The serious nature of alloimmune thrombocytopenia is emphasized, and current modes of risk assessment and therapy are discussed.
Collapse
|
114
|
Fernandez-Miranda C, Mateo S, Kessler P, Gonzalez-Castelló J. Immune thrombocytopenia and ulcerative colitis. J Clin Gastroenterol 1994; 18:85-6. [PMID: 8113594 DOI: 10.1097/00004836-199401000-00020] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
|
115
|
Sieff C, Guinan E. In vitro enhancement of erythropoiesis by steel factor in Diamond-Blackfan anemia and treatment of other congenital cytopenias with recombinant interleukin 3/granulocyte-macrophage colony stimulating factor. Stem Cells 1993; 11 Suppl 2:113-22. [PMID: 7691316 DOI: 10.1002/stem.5530110819] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Recombinant cytokines were used to investigate the pathophysiology of Diamond-Blackfan anemia (DBA) and to treat patients with Fanconi's anemia (FA) and amegakaryocytic thrombocytopenic purpura (AMT). We compared the erythroid burst forming units (BFU-E) colony growth of six DBA patients with four normal controls. BFU-E showed erythropoietin (Epo) dose dependence in all patients, although colony numbers were reduced in comparison with normals. The number and size of BFU-E were increased with the addition to Epo of interleukin 3 (IL-3) or Steel factor (SF), but IL-3 + SF was not synergistic. SF increased the nonadherent cell production in DBA long-term bone marrow cultures, and stromal cells from DBA patients showed normal SF mRNA transcripts. These data suggest that SF is not involved in the pathogenesis of DBA, although it may be useful in treatment. A small group of patients with FA and bone marrow failure were treated with daily s.c. granulocyte-macrophage colony stimulating factor (GM-CSF). Toxicity was minimal, and the majority of the patients responded with significant, sustained increase in neutrophils. Multilineage response was rare. GM-CSF may thus be palliative in patients with FA. Five patients with AMT were treated with IL-3 or IL-3 followed by GM-CSF in a phase I/II study. There was minimal toxicity, and IL-3, but not GM-CSF, resulted in improved platelet counts in two patients and decreased platelet transfusion requirements in the other three. Prolonged IL-3 treatment resulted in platelet increases in two of the latter patients. Thus, IL-3 may contribute to the treatment of patients with AMT.
Collapse
|
116
|
Durand JM, Lefevre P, Telle H, Kaplanski G, Quiles N, Soubeyrand J. Thrombocytopenic purpura and hepatitis C virus infection. Haematologica 1993; 78:135. [PMID: 8349192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
|
117
|
Tan E, Hajinazarian M, Bay W, Neff J, Mendell JR. Acute renal failure resulting from intravenous immunoglobulin therapy. ARCHIVES OF NEUROLOGY 1993; 50:137-9. [PMID: 8431131 DOI: 10.1001/archneur.1993.00540020015010] [Citation(s) in RCA: 95] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
In idiopathic thrombocytopenic purpura, a known immune-mediated disorder, intravenous IgG is the treatment of choice. Success and the lack of side effects of intravenous IgG in the treatment of idiopathic thrombocytopenic purpura have encouraged consideration of its use in the treatment of neurologic disorders of presumed autoimmune pathogenesis. In this report, we describe two patients who developed acute renal failure following intravenous IgG treatment. The first patient had chronic inflammatory demyelinating polyneuropathy and was treated with intravenous IgG instead of prednisone because of preexisting diabetes. The second patient had idiopathic thrombocytopenic purpura and received intravenous IgG treatment as part of standard care. The patient with idiopathic thrombocytopenic purpura had unrelated bilateral high-grade renal artery stenosis. Both patients had a creatinine level of 140 mumol/L (1.6 mg/dL) prior to treatment. Renal biopsies performed during acute renal failure in each patient demonstrated marked swelling and vacuolization of the proximal tubular epithelial cytoplasm typical of high-solute-load-induced damage (similar to that associated with the use of mannitol). This report draws attention to the importance of screening for impaired renal function before intravenous IgG therapy is initiated. The patients we describe received standard doses of intravenous IgG at the recommended infusion rate yet developed oliguric renal failure. Awareness of serious side effects and recognition of predisposing factors provide means of avoiding known life-threatening complications of intravenous IgG therapy.
Collapse
|
118
|
Behrenbeck U, Riedel F, Rieger CH. Increase in platelet count following short course therapy with recombinant alpha-2b-interferon in immune thrombocytopenic purpura in childhood. Pediatr Allergy Immunol 1993; 4:10-2. [PMID: 8348249 DOI: 10.1111/j.1399-3038.1993.tb00058.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Two boys, aged three and seven years with immune thrombocytopenic purpura continued to show platelet counts below 20,000/mm3 inspite of treatment with high dose gammaglobulin and steroids. Alpha-2b-interferon injections were followed by normalisation of platelet counts in both patients. No side effects were seen. Alpha-interferon may be a safe and effective treatment for childhood-ITP.
Collapse
|
119
|
Dragoni F, Arcieri R, Chistolini A, De Sanctis V, Pasqualetti D, Mazzucconi MG. Splenectomy outcome in a hemophilic patient with HIV-related immune thrombocytopenia. Haematologica 1993; 78:61-3. [PMID: 8098312] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
We report the case of a young hemophilic patient with antibodies against the human immunodeficiency virus (HIV) who was affected by immune thrombocytopenic purpura (ITP). This condition did not respond to pharmacological therapy with steroids and alpha-2b-r-IFN, and the patient was splenectomized. Immune status evaluation was performed before and after surgery and during follow-up with CD4-CD8 monoclonal antibodies and cytofluorimetric analysis in order to explore possible correlations between splenectomy and the cytologic immune regulatory system. Splenectomy resulted in a resolution of ITP with consequent disappearance of the hemorrhagic diathesis related to thrombocytopenia. Moreover, at 30 months from splenectomy the patient is still in remission, his CD4 count is not decreased, and no progression to AIDS has been evidenced. These aspects are analyzed and briefly discussed.
Collapse
|
120
|
Nimura Y, Morimoto M, Nohara H, Fukaya Y, Nishimura K, Nakano H, Miwa H, Yanagiya N, Shinohara M, Haruta S. [A case of aortic valve stenosis and regurgitation with idiopathic thrombocytopenic purpura]. KYOBU GEKA. THE JAPANESE JOURNAL OF THORACIC SURGERY 1992; 45:1120-2. [PMID: 1383588] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
A patient of aortic valvular disease with idiopathic thrombocytopenic purpura underwent aortic valvular replacement. We report a preventive measure against the intra and postoperative bleeding. The patient was a 67-year-old man. He was diagnosed as aortic valvular stenosis with regurgitation. There was no abnormal data about the coagulation test. Thrombocyte count was 8.2 x 10(4)/mm3, but thrombocytopenic life span had shortened 3.8 days. So, we used gamma-globulin 400 mg/kg/day for 5 days before the day of operation and infused blood platelets on the day of operation. There was no problem intra and postoperative period. On the 14th postoperative day thrombocyte count increased to 22.9 x 10(4)/mm3, and thrombocytopenic life span returned to normal range (7.6 days). But on the 45th day of postoperation, thrombocyte count decreased to 11.0 x 10(4)/mm3. We think that many gamma-globulin medication is a useful method to prevent intra and postoperative bleeding resulting from idiopathic thrombocytopenic purpura.
Collapse
|
121
|
Nugent DJ. Alloimmunization to platelet antigens. Semin Hematol 1992; 29:83-8. [PMID: 1509298] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Alloantibodies to platelet-specific antigens can cause significant thrombocytopenia and bleeding in NATP and PTP. IVIG plays an important role in the therapeutic regimen of both of these disorders. Alloantibodies in the multiply transfused patient bind to HLA class I and platelet-specific antigens. IVIG has not improved response to random-donor platelets in refractory patients, but there may be a role for IVIG in critically ill and bleeding patients, in combination with HLA-matched platelets.
Collapse
|
122
|
|
123
|
Abstract
Onyalai is an acquired form of immune thrombocytopenia which differs clinically, epidemiologically and immunologically from idiopathic thrombocytopenic purpura (Table 4). The clinical hallmark is haemorrhagic bullae on the mucosa of the oronasopharynx. Haemorrhage from ruptured bullae, epistaxis or gastrointestinal bleeding is severe and may cause shock and death. The disease is limited to some black populations of central southern Africa, with a recorded incidence of one per 660 inhabitants per year in the Kavango territory of Namibia. The majority of patients demonstrate both IgG and IgM serum platelet antibodies and serum platelet glycoprotein IIb/IIIa autoantibodies. Chronic thrombocytopenia often ensues and recurrent episodes of clinical bleeding are common. Treatment directed at the prevention of haemorrhagic shock reduced the mortality rate in the acute phase from 9.8 to 2.8%. Standard dose prednisolone does not increase the platelet count. Vincristine sulphate may benefit some patients and splenectomy is indicated in patients with severe uncontrollable haemorrhage. High dose intravenous gammaglobulin may be followed by a rise in the platelet count and cessation of haemorrhage. The aetiology is unknown. The possible aetiological role of mycotoxins from contaminated millet, sorghum or maize requires further investigation.
Collapse
|
124
|
Nugent DJ. IVIG in the treatment of children with acute and chronic idiopathic thrombocytopenic purpura and the autoimmune cytopenias. CLINICAL REVIEWS IN ALLERGY 1992; 10:59-71. [PMID: 1606524 DOI: 10.1007/978-1-4612-0417-6_5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
IVIG has been shown to be useful in the treatment of acute and chronic ITP, immune neutropenia, and in some cases of AIHA. The mechanism of action of IVIG is owing to a number of factors, which include Fc blockade, immune modulation of T- and B-cell number and function, alterations in NK activity, and direct effects on autoantibody binding and production via the antiidiotypic antibody network. Current research efforts are directed toward elucidation of these modalities and determination of their relative importance in treating patients with immune-mediated cytopenias.
Collapse
|
125
|
Kurtzberg J, Dunsmore KP. IVIG therapy in neonatal isoimmune thrombocytopenic purpura and alloimmunization thrombocytopenia. CLINICAL REVIEWS IN ALLERGY 1992; 10:73-80. [PMID: 1606525 DOI: 10.1007/978-1-4612-0417-6_6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|